Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
N-tert-Butyl-alpha-phenylnitrone [PBN]
61
CHF
CHF 61.00
In stock
CDX-B0269-G0011 gCHF 61.00
CDX-B0269-G0055 gCHF 244.00
| Product Details | |
|---|---|
| Synonyms | Phenyl N-t-butylnitrone; N-tert-Butyl-α-phenylnitrone; N-Benzylidene-N-(2-methyl-2-propanyl)amine oxide; (Z)-N-Benzylidene-2-methylpropan-2-amine oxide |
| Product Type | Chemical |
| Properties | |
| Formula | C11H15NO |
| MW | 177.2 |
| CAS | 3376-24-7 |
| RTECS | TX1760000 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (GC) |
| Appearance | Off-white to white crystals. |
| Solubility | Soluble in DMSO. |
| Identity | Determined by NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | IYSYLWYGCWTJSG-UHFFFAOYSA-N |
| Smiles | CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Cell permeable spin trap commonly used in free radical research for both in vivo and in vitro studies. It protects against oxidative damage caused by various inflammatory events, demonstrating neuroprotective, anti-anging, and antidiabetic effects. PBN has been shown to inhibit LPS-induced NF-κB DNA binding activity, inhibit COX-2 catalytic activity, inhibit lipid peroxidation in rat liver microsomes and prevent the induction of inducible nitric oxide synthase (iNOS). Shows anti-cancer activity in several experimental cancer models.
Product References
(1) R.A. Floyd; FASEB J. 4, 2587-4597 (1990) | (2) R.F. Haseloff; FEBS Lett. 418, 73 (1997) | (3) R.A. Floyd; Adv. Pharmacol. 38, 361 (1997) | (4) T. Miyajima & Y. Kotake; Free Radic. Biol. Med. 22, 463 (1997) | (5) Y. Kotake, et al.; Biochim. Biophys. Acta 1448, 77 (1998) | (6) R.A. Floyd; Proc. Soc. Exp. Biol. Med. 222, 236 (1999) (Review) | (7) Y. Kotake; Antioxid. Redox Signal. 1, 481 (1999) (Review) | (8) E. Ho, et al.; Free Radic. Biol. Med. 28, 604 (2000) | (9) P. Kelicen, et al.; Neuroreport 13, 1057 (2002) | (10) W.N. Hassan, et al.; Free Radic. Biol. Med. 32, 551 (2002) | (11) K. Saito & H. Yoshioka; Free Radic. Res. 36, 143 (2002) | (12) R.A Floyd; Anticanc. Agents Med. Chem. 11, 373 (2011)
Related Products
